Education
About Us
Working with TipRanks
Follow Us
SynAct Pharma AB (SE:SYNACT)
:SYNACT
Top Page
SynAct Pharma AB
(Frankfurt:SYNACT)
Rating:48Neutral
Price Target:―
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr916.47M
Dividend YieldN/A
Average Volume (3M)271.46K
Price to Earnings (P/E)―
Beta (1Y)-0.26
Revenue GrowthN/A
EPS Growth67.70%
CountrySE
Employees6
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding49,008,920
10 Day Avg. Volume419,354
30 Day Avg. Volume271,461
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)3.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SynAct Pharma AB Business Overview & Revenue Model
Company DescriptionSynAct Pharma AB (SYNACT) is a biotechnology company focused on the development of pharmaceuticals for the treatment of inflammatory diseases. The company's primary aim is to advance therapies that can modulate the body's immune response to inflammation, targeting unmet medical needs across various conditions. SynAct Pharma's lead product candidate is designed to leverage its platform technology to achieve these therapeutic goals.
How the Company Makes MoneySynAct Pharma makes money primarily through the development and eventual commercialization of its pharmaceutical products. Revenue streams are expected to include licensing agreements, partnerships with larger pharmaceutical companies, and sales of its developed drugs upon regulatory approval. The company may also receive milestone payments and royalties from its partnerships. As typical in the biotech sector, SynAct Pharma may also rely on funding from investors and grants to support ongoing research and development activities until its products reach the market.
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -778.00K | -1.06M | -88.00K | 0.00 | -338.51K | EBIT |
| -89.75M | -224.50M | -105.70M | -76.70M | -31.29M | -24.80M | EBITDA |
| -89.98M | -222.70M | -105.71M | -76.62M | -30.90M | -25.01M | Net Income Common Stockholders |
| -82.40M | -215.81M | -99.20M | -69.30M | -26.55M | -23.96M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 61.21M | 62.40M | 108.25M | 24.00M | 14.55M | 3.56M | Total Assets |
| 270.52M | 228.02M | 142.60M | 38.37M | 21.59M | 23.81M | Total Debt |
| 1.88M | 637.00K | 2.06M | 3.09M | 0.00 | 0.00 | Net Debt |
| -59.33M | -61.76M | -106.18M | -20.91M | -14.55M | -3.56M | Total Liabilities |
| 56.35M | 51.83M | 16.08M | 17.50M | 5.72M | 10.31M | Stockholders Equity |
| 214.17M | 176.19M | 126.52M | 20.87M | 15.87M | 13.50M |
| Cash Flow | Free Cash Flow | ||||
| -89.20M | -100.18M | -117.56M | -65.00M | -33.24M | -16.62M | Operating Cash Flow |
| -89.20M | -100.18M | -117.56M | -65.00M | -33.24M | -16.12M | Investing Cash Flow |
| 0.00 | 370.00K | 27.00K | -6.00K | -93.00K | -499.00K | Financing Cash Flow |
| 87.40M | 53.98M | 200.71M | 74.32M | 44.72M | 13.00M |
SynAct Pharma AB Technical Analysis
Negative
13.98
Price Trends
18.01
Negative
16.43
Negative
12.77
Positive
Market Momentum
-0.88
Positive
41.81
Neutral
29.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 13.98 is below the 20-day moving average (MA) of 17.86, below the 50-day MA of 18.01, and above the 200-day MA of 12.77, indicating a neutral trend. The MACD of -0.88 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 29.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr1.30B | 4.81 | 152.78% | ― | 1533.99% | ― | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
48 Neutral | kr916.47M | ― | -48.22% | ― | ― | 67.70% | |
47 Neutral | kr1.16B | ― | -42.24% | ― | ― | -19.44% | |
41 Neutral | kr372.93M | ― | -194.31% | ― | 1643.36% | 50.36% | |
40 Underperform | kr322.39M | ― | ― | 1.72% | 32.54% | ||
31 Underperform | kr310.76M | ― | -167.55% | ― | ― | 46.67% |
* Healthcare Sector Average
Performance Comparison
SE:SYNACT
SynAct Pharma AB
18.72
11.79
170.29%
SE:ONCO
Oncopeptides AB
1.52
-2.12
-58.24%
SE:CANTA
Cantargia AB
1.16
-3.58
-75.47%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
7.19
-6.96
-49.19%
SE:SANION
Saniona AB
9.30
6.24
203.43%
SE:XSPRAY
Xspray Pharma AB
31.30
-39.65
-55.88%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.